Roche (RHHBY) announced it has received CE-IVDR approval for two label expansions of its VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx assay.
The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in assessing HER2-ultralow status in metastatic breast cancer patients who may be eligible for treatment with ENHERTU. It is also approved to help identify patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.